Research Appraisalobservational

Proteome atlas for mechanistic discovery and risk prediction of diabetic retinopathy

Nat CommunYang, Shaopeng, Xin, Zhuoyao, Xiong, Ruilin et al.1 Oct 2025DOI

Clinical Snapshot

80CEBM
Evidence: Moderateobservational

PICO Framework

P — Population10,873 individuals with (pre)diabetes from two ethnically distinct cohorts
I — InterventionProteomic profiling of ~3000 proteins
C — ComparatorClinical and genetic predictors alone
O — OutcomesDiabetic retinopathy development and progression, retinal microvascular degeneration

Bottom Line

This large-scale proteomic study of over 10,000 individuals with diabetes identifies 668 protein associations with diabetic retinopathy, with cross-cohort validation highlighting plexin B2, growth differentiation factor 15, and renin as key biomarkers. A parsimonious 3-protein panel achieved comparable predictive performance to comprehensive proteomic profiling, with renin confirmed as a causal promoter through genetic analysis. The integration of proteomic profiles markedly improved prediction beyond traditional clinical and genetic factors. While promising for biomarker discovery and mechanistic understanding, clinical implementation requires validation of cost-effectiveness and integration with existing screening protocols. The cross-ethnic validation enhances generalisability, though Australian-specific validation would strengthen local applicability.

Evidence: Moderate

Key Findings

  • P Value: Not reported in abstract

  • Effect Size: Top proteins: plexin B2, growth differentiation factor 15, and renin

  • Primary Outcome: 668 protein associations with diabetic retinopathy identified

  • Nnt Or Sensitivity: Parsimonious 3-protein panel achieves comparable predictive performance to full proteomic profile

  • Confidence Interval: Not reported in abstract

Clinical Application

Proteomic testing may be feasible in specialist centres but cost-effectiveness needs evaluation Could complement existing RACGP diabetes management guidelines and PBS-funded DR screening programs, particularly for high-risk patients Adults with diabetes or prediabetes requiring DR screening

Abstract

Proteomics offers an unprecedented opportunity to characterize and predict diabetic retinopathy (DR) with minimal invasiveness. Here we examine this in 10,873 individuals with (pre)diabetes from two ethnically distinct cohorts. By simultaneous profiling of ~3000 proteins, we identify 668 associations with mechanistically plausible directionality that constitute a comprehensive DR proteomic landscape with linkages to retinal tomographic structure and genetic predisposition, pointing to established and novel biological pathways conferring DR risk. Integrating DR proteomic profile markedly improves predictive performance beyond clinical and genetic predictors, with plexin B2, growth differentiation factor 15, and renin emerging as top proteins validated across cohorts and linked to retinal microvascular degeneration in Guangzhou Diabetic Eye Study (GDES) based on SS-OCTA. A parsimonious panel of these three proteins alone achieves comparable performance in predicting DR development and progression, while renin is confirmed as a causal promoter through genetic analyses. Our findings highlight the potential of large-scale proteomics in elucidating DR pathogenesis and advancing biomarker discovery, with broad implications for early detection and intervention.

References

  1. 1.Yang, S., Xin, Z., Xiong, R., Zhu, Z., Li, H., Chen, Y., Zhong, Z., Du, L., Zhu, L. Z., Shang, X., Huang, W., Zhang, L., Chen, S., He, C., Tan, S., He, M., Congdon, N., Jonas, J. B., Tham, Y.-C., Cheng, C.-Y., & Wang, W. (2025). Proteome atlas for mechanistic discovery and risk prediction of diabetic retinopathy. Nature Communications. https://doi.org/10.1007/s00125-020-05134-3
Share:XLinkedIn

This content is for educational purposes for healthcare professionals only and does not constitute clinical advice. Clinical decisions should be based on individual patient assessment, current guidelines, and appropriate specialist consultation. Editorial Standards · Privacy Policy · Terms of Service